• David Jiménez Gallo, Cristina Albarrán Planelles, Mario Linares Barrios, María José Fernández Anguita, Juan Márquez Enríquez, and María Eugenia Rodríguez Mateos.
• Department of Dermatology, Puerta del Mar University Hospital, Cadiz, Spain.
• Dermatol Ther. 2014 May 1;27(3):178-82.

AbstractPruritus is a symptom that significantly affects the patient's quality of life in cutaneous T cell lymphoma (CTCL). The most effective treatments are those that address the condition itself; however, it is often not possible to control this symptom. Lymphoma-related pruritus normally becomes more severe as CTCL progresses, constituting an important factor for quality of life in these patients. Substance P is a neuromodulator which appears to play a key role in pruritus. Aprepitant is a neurokinin-1 receptor antagonist affecting the substance P receptor. So far, several cases have been documented with an antipruritic response to the drug aprepitant in advanced-stage mycosis fungoides (MF). In this paper, we describe an excellent response to aprepitant in a female patient with severe pruritus secondary to hypopigmented stage I MF. We would also like to stress the absence of nausea and vomiting of this combined therapy of interferon and aprepitant. Aprepitant could improve tolerance to interferon.© 2013 Wiley Periodicals, Inc.

23 keywords...

hide…